相关实验视频

Updated: Jun 30, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

在NSCLC-A系统性审查中揭示了不常见的EGFR突变的风景

Maxime Borgeaud1, Kaushal Parikh2, Giuseppe Luigi Banna3

  • 1Oncology Department, University Hospital Geneva (HUG), Geneva, Switzerland.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
|March 18, 2024
PubMed
概括

第二代氨酸激酶抑制剂 (TKI) 对不常见的EGFR突变,如G719X和S768I,显示出有效性. 第三代TKI可能有利于L861Q突变的患者,为非小细胞肺癌提供量身定制的治疗选择.

关键词:
根据 EGFR PACC 的突变.非小细胞肺癌是什么?系统性审查 系统性审查铁氨酸激酶抑制剂 铁氨酸激酶抑制剂不常见的EGFR突变

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

相关概念视频